Skip to main content
OpenTrials
Completed

NCT Number: NCT01989819

Primary Sjögren Syndrome

Primary Sjögren syndrome (pSS) is an inflammatory, autoimmune, multiorgan disease often involving the central and peripheral nervous systems. Fifteen to twenty percent of patients with the primary Sjögren's syndrome have neurological complications involving the peripheral nervous system. Although some patients have large fiber neuropathy, around forty percent of patients with Sjögren's syndrome experience neuropathic pain with normal electrodiagnostic studies. Although these patients may be diagnosed with fibromyalgia or depressive symptoms, some have been shown to have small fiber neuropathy (SFN). A recent study proved that more than 90% of pSS patients with such neuropathic pain have SFN {Fauchais, 2010 #188}.

The aim of this study will be to investigate the occurrence of small fiber neuropathy in patients with pSS and neuropathic pain with normal electromyographic studies and to determine the existence of a conjoint local inflammatory process mediated by cellular, cytokinic or auto-antibody response. Quantification of epidermal nerve fiber density after skin biopsy is a valuable tool to diagnose small fiber neuropathy and the method has been widely validated. A skin biopsy will be performed in patients and control and will allow quantification of small fiber density in skin sample along with measurement of sweat gland innervation. Moreover, pathophysiological studies will be carried on in order to evaluate the causal relationship between cellular and humoral inflammation and small fiberneuropathy.

Recent studies have pointed out the inconstant efficacy of both corticosteroid and immunosuppressive drugs in pSS-related SFN. Dissecting the molecular mechanisms of small fiber neuropathy in these patients may help designing new therapeutic strategies.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CH d'Albi, Albi, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with pSS according to revised European criteria and exhibiting neuropathic pain without any electromyographic abnormality will be included (Group I).
  • Age of entry into the study ≥ 18 yrs (both groups).
  • Affiliated or profit patient of a social security system (both groups).
  • Informed consent signed up (both groups).

Exclusion criteria

  • Chronic alcoholism
  • Type I or type II diabetes
  • Peripheral neuropathy unrelated to pSS complications
  • Coagulation disease
  • Previous allergy to xylocaine, lidocaine, prilocaine or ricin oil
  • Porphyria, methemoglobinemia
  • Patients under measure of maintenance of justice.
  • Patients unable to understand or to participate to the study.
  • Child and major patients making the object of a measure of lawful protection.
  • Patients deprived of freedom.
  • Pregnant, nursing women.
  • Participation in biomedical research within one month prior to inclusion.

Treatment and study plan

Skin biopsy

Other

Primary outcomes

  1. To evaluate the cutaneous lymphocytic infiltration

    Time frame: 1 year

Secondary outcomes

  1. Cutaneous infiltration T, B and Th17

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

University Hospital, Limoges

Other

Registry information

Acronym: NeuroSenSS

Important dates

Study start
2012
Primary completion
2016
Study completion
2017
First posted
Nov 21, 2013
Registry last updated
Jan 11, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.